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Anti-neutrophil cytoplasmic antibodies (ANCAs) have a
pathogenic role in ANCA-associated vasculitis. The origin of
ANCAs and anti-glomerular basement membrane (GBM)
antibodies, however, is unknown. In this study, we
determined whether natural autoantibodies against
myeloperoxidase (MPO), proteinase 3 (PR3), and GBM
were present in each of 10 healthy Chinese and Swedish
individuals, negative for all three antigens by routine ELISA.
Antibodies were purified from isolated IgG by antigen-
specific affinity columns. Natural anti-GBM autoantibodies
gave a linear staining pattern along the GBM of human renal
sections. On ethanol-fixed granulocytes, both natural anti-
MPO and anti-PR3 autoantibodies gave cytoplasmic staining.
The titers of natural anti-MPO/PR3 autoantibodies were
significantly lower than those from patients with vasculitis.
In competition ELISA, the binding of natural anti-MPO
autoantibodies could be inhibited by MPO, but not by
PR3 or noncollagenous domains from type IV collagen.
The same specificity results were found for natural anti-PR3
and anti-GBM autoantibodies. Overall, individuals of the
Chinese origin had more natural autoantibodies than did
those of the Swedish origin, but no other differences were
found. Hence, our study shows that healthy individuals
have masked circulating, noncross-reactive, antigen-specific
natural autoantibodies against MPO, PR3, and GBM in their
serum and IgG fractions. Further studies are needed to
determine their role if any in the etiology of ANCA-associated
vasculitis and anti-GBM disease.
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Anti-neutrophil cytoplasmic antibodies (ANCAs)-associated
vasculitis includes Wegener’s granulomatosis, microscopic
polyangiitis, Churg–Strauss syndrome, and renal-limited
vasculitis.1 The major antigen specificities of ANCA are
myeloperoxidase (MPO)2 and proteinase 3 (PR3).3 Substan-
tial evidence suggests that ANCAs have a crucial role in
the pathogenesis of vasculitis.4–7 After immunization of
MPO-knockout (Mpo/) mice with mouse MPO, the
direct pathogenic effect of anti-MPO immunoglobulin (Ig)G
has been convincingly demonstrated by adoptive transfer
of anti-MPO-positive splenocytes into Rag2/ mice and
by passive transfer of anti-MPO IgG alone into wild-type
mice.8 Another demonstration is the report of transplacental
transfer of anti-MPO antibodies from a mother with
microscopic polyangiitis to a neonate, who developed a
reno-pulmonary syndrome.9 In PR3-ANCA vasculitis, many
questions regarding the pathogenic role of anti-PR3 anti-
bodies are still open. Rising titers of PR3-ANCA have been
shown to predict a relapse of disease.10 However, others
could not confirm this correlation.11
Goodpasture’s disease (GP), also known as anti-
glomerular basement membrane (GBM) disease, is character-
ized by circulating antibodies against GBM and a linear
deposition of IgG along the glomerular and pulmonary alveolar
basement membranes.12,13 Goodpasture’s antigen has been
defined as the noncollagenous (NC1) domain of the a3 chain of
type IV collagen (a3(IV)NC1) in the GBM.14,15 The patho-
genicity of anti-GBM antibodies was fully demonstrated by a
passive transfer experiment. Eluted Ig from a GP patient’s
kidney was injected into the circulation of monkeys, which
developed a glomerulonephritis immediately after the transfer.16
Although ANCAs and anti-GBM antibodies have an
important role in the pathogenesis of vasculitis and GP,
their origin is still unknown. Natural autoantibodies (NAAs)
refer to the antibodies, circulating in healthy individuals,
which have been produced in the absence of overt specific
antigenic stimulation.17 Most NAAs are autoantibodies and
react with self-antigens that are targets for antibodies in
autoimmune diseases.18 Recently, we reported the existence
of NAAs against the GBM in healthy individuals. Lower titer,
lower affinity, as well as IgG2 and IgG4 subclass restriction of
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natural anti-GBM antibodies support the hypothesis that
they are not prone to induce an autoimmune response, but
may be protective autoantibodies.19 Salama et al. showed
that a3(IV)NC1 is expressed in the thymus, but CD4þ
T cells with reaction to such antigens escape the thymic
deletion and participate in the development of GP.20,21
Recent studies have also suggested that normal individuals
possess a3(IV)NC1-responsive naive T cells.22 These findings
support the notion that, as in other autoimmune diseases,
central tolerance toward the a3(IV)NC1 is incomplete, and
B and T cells specific for autoepitopes are not deleted and/or
not rendered anergic.
No study focuses on natural anti-MPO antibodies or
natural anti-PR3 antibodies, but there is evidence that
healthy individuals have idiotypic anti-anti-MPO anti-
bodies.23 The aim of this study was to demonstrate the
existence of NAAs against MPO, PR3, and GBM in 10 healthy
Chinese individuals and in 10 Swedish individuals. Antigen
specificity and cross-reactivity among the three kinds of
NAAs were investigated and compared between the Chinese
and Swedish samples.
RESULTS
Purification of NAAs from normal human plasma
NAAs against MPO, PR3, and GBM were purified from IgG
fractions from all the 20 individuals. Purity of the isolated
NAAs was confirmed by silver staining of SDS-PAGE mini-
gel with 10% SDS-PAGE mini-gels. The major protein of
all the 20 preparations was IgG with very few other proteins.
Under the reducing condition, 25-kDa (light chains) and
50-kDa (heavy chains) proteins of IgG could be stained
identically to the standard human IgG (Figure 1).
Antigen specificity of NAAs
Antigen specificity of NAAs was first investigated by
indirect immunofluorescence (IIF). When applied to
ethanol, fixed granulocytes from healthy donors, NAAs
eluted from the anti-PR3 column yielded a typical cyto-
plasmic staining pattern (c-ANCA). Interestingly, all 20
NAA fractions recovered from the anti-MPO column also
yielded a c-ANCA pattern (Figure 2). The natural anti-
GBM antibodies were subjected to IIF using normal
human renal sections. Eluates from all of the 20 donors
produced a linear staining along the glomerular capillary
walls (Figure 3).
The antigen specificity of NAAs was also investigated
by enzyme-linked immunosorbent assay (ELISA) using puri-
fied human MPO, human PR3, and bovine testis NC1 as
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Figure 1 | The purity of natural autoantibodies against MPO,
PR3, and GBM was detected by silver staining of SDS-PAGE
mini-gels. Under reducing conditions, 25-kDa (light chains) and
50-kDa (heavy chains) bands of IgG could be stained identically to
the standard human IgG sample. Lanes 1–4: natural anti-GBM
antibodies (C1, C7, C10, S7); lanes 5–8: natural anti-MPO
antibodies (C1, C6, S1, S7); lanes 9–12: natural anti-PR3 antibodies
(C1, C10, S1, S7); lanes 13–14: standard human IgG sample (0.5,
0.25mg); lane M: molecular weight marker. C: NAA from Chinese
individuals; S: NAA from Swedish individuals. GBM, glomerular
basement membrane; IgG, immunoglobulin G; MPO,
myeloperoxidase; NAA, natural autoantibody; PR3, proteinase 3.
a b
Figure 2 | Indirect immunofluorescence on neutrophils. Natural
anti-MPO and anti-PR3 antibodies from all donors were screened
for ANCA by indirect immunofluorescence and presented a
cytoplasmic staining pattern (c-ANCA) on precooled ethanol-fixed
normal peripheral neutrophils. (a) Natural anti-MPO antibodies
(original magnification  600). (b) Natural anti-PR3 antibodies
(original magnification  600). ANCA, anti-neutrophil cytoplasmic
antibody; MPO, myeloperoxidase; PR3, proteinase 3.
Figure 3 |The antigen recognition of natural anti-GBM
antibodies was identified by indirect immunofluorescence.
On frozen normal human renal sections, the linear staining of IgG
along the glomerular capillary walls was revealed after incubation
with natural anti-GBM antibodies (original magnification  600).
GBM, glomerular basement membrane; IgG, immunoglobulin G.
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solid-phase antigens. The natural anti-MPO antibodies
bound MPO, and no reactivity was found against PR3 or
NC1. In a similar manner, natural anti-PR3 and anti-GBM
antibodies bound their target antigens without showing any
reactivity to other antigens.
The antigen specificity of NAAs was further identified by
western blot analysis using recombinant human a3(IV)NC1
as a solid-phase antigen. Under the nonreducing condition,
25-kDa bands of a3(IV)NC1 were identically recognized
by natural anti-GBM antibodies and the positive control
(the sera obtained from a patient with GP). No specific
binding was found for natural anti-MPO or anti-PR3
antibodies against a3(IV)NC1 (Figure 4).
Titers of natural anti-MPO and anti-PR3 antibodies compared
with those obtained from patients with vasculitis
The mean titer of natural anti-MPO antibodies was 1:25.2
(log10n¼ 1.40±0.32), whereas the mean titer of MPO-
ANCA obtained from the sera of patients with vasculitis
was 1:649.8 (log10n¼ 2.81±0.65). The mean titer of natural
anti-PR3 antibodies was 1:31.4 (log10n¼ 1.50±0.38), where-
as the mean titer of PR3-ANCA obtained from the sera
of patients with vasculitis was 1:708.6 (log10n¼ 2.85±0.62).
Titers of natural anti-MPO/PR3 antibodies were much lower
than those of MPO/PR3-ANCA from patients with vasculitis
(Po0.001) (Figure 5).
Cross-reactivity among NAAs against the three antigens
Cross-reactivity of NAAs against the three different antigens
were detected by antigen inhibition ELISA using purified
human MPO, human PR3, and bovine testis NC1 proteins
to inhibit the binding of NAA to their target antigens.
The binding of natural anti-MPO antibodies to MPO
could be inhibited by MPO alone, but not by PR3 or NC1.
The binding of natural anti-PR3 antibodies to PR3 could
be inhibited merely by PR3, but not by MPO or NC1.
In addition, the binding of natural anti-GBM antibodies
to NC1 could be inhibited by NC1 exclusively, but not by
MPO or PR3 (Figure 6).
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Figure 4 | The antigen specificity of natural anti-GBM, anti-MPO, and anti-PR3 antibodies was identified by western blot analysis.
Under nonreducing conditions, the 25-kDa band of recombinant human a3(IV)NC1 could be recognized by natural anti-GBM antibodies
identically to the positive control, but not by natural anti-MPO or anti-PR3 antibodies. Lane M: molecular weight marker; lane 1: positive
control of anti-GBM antibodies (sera from a patient with Goodpasture’s disease); lane 2: positive control of anti-MPO antibodies (sera from
a patient with MPO-ANCA-positive microscopic polyangiitis); lane 3: positive control of anti-PR3 antibodies (sera from a patient with
PR3-ANCA-positive Wegener’s granulomatosis); lane 4: negative control (sera from a normal individual without anti-GBM/MPO/PR3
antibodies); lane 5: blank (TBST); lanes 6–10: natural anti-GBM antibodies (C1, C3, C5, C7, C9); lanes 11–15: natural anti-GBM antibodies
(S2, S4, S6, S8, S10); lanes 16–18: natural anti-MPO antibodies (C1, C4, C7); lanes 19–21: natural anti-MPO antibodies (S2, S5, S8); lanes 22–24:
natural anti-PR3 antibodies (C1, C4, C7); lanes 25–27: natural anti-PR3 antibodies (S2, S5, S8). C: NAA from Chinese individuals; S: NAA from
Swedish individuals. ANCA, anti-neutrophil cytoplasmic antibody; GBM, glomerular basement membrane; MPO, myeloperoxidase; NAA,
natural autoantibody; PR3, proteinase 3.
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Figure 5 |Comparison of ANCA titers. (a) Titers of natural
anti-MPO antibodies were compared with MPO-ANCA from
patients with vasculitis. (b) Titers of natural anti-PR3 antibodies
were compared with PR3-ANCA from patients with vasculitis.
*Po0.001. ANCA, anti-neutrophil cytoplasmic antibody; MPO,
myeloperoxidase; NAA, natural autoantibody; PR3, proteinase 3.
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Comparison of NAAs between Chinese and Swedish
individuals
The observed amounts of NAAs against MPO, PR3, and
GBM were higher in Chinese individuals than in Swedish
individuals. Anti-MPO NAAs accounted for 0.19±0.04% of
the total IgG fraction in the 10 Chinese individuals and
for 0.14±0.04% in the 10 Swedish individuals (P¼ 0.006).
For anti-PR3 antibodies, NAAs accounted for 0.98±0.30% of
the total IgG fraction in the 10 Chinese individuals and for
0.78±0.14% in the 10 Swedish individuals (P¼ 0.064). Anti-
GBM NAAs accounted for 0.68±0.20% of the total IgG
fraction in the 10 Chinese individuals and for 0.37±0.11% in
Swedish individuals (P¼ 0.039) (Table 1).
No other differences of the characteristics of NAA were
found between Chinese and Swedish individuals, including
the purity, antigen specificity, and cross-reactivity of NAA.
DISCUSSION
In the current study, we found that healthy individuals
possess NAAs against MPO, PR3, and GBM, which could be
affinity isolated from IgG fractions of normal human plasma,
but could not be detected in the original plasma or their
IgG fractions. To our knowledge, this is the first report in
which NAAs against MPO and PR3 are identified. The
antigen specificity of NAAs was confirmed by IIF and ELISA
and no cross-reactivity could be demonstrated. The finding
of NAAs against MPO, PR3, and GBM in all 20 individuals
with similar characteristics indicates that they might exist in
all human beings.
Regulatory processes that govern the development of
T and B cells are supposed to prevent the development
of autoreactive cells. However, there is compelling evidence
that healthy individual do develop autoreactive B and T cells,
including natural anti-MPO and anti-PR3 antibodies found
in the current study. The fact that these antibodies are of IgG
subclass indicates an antigen-driven maturation process of B
cells. This is supported by the finding of MPO- and PR3-
reactive T cells in healthy individuals.24 It was inferred that
these autoreactive cells have escaped the normal control for
MPO and PR3, like the incomplete central tolerance toward
a3(IV)NC1. In this study, we investigated only NAAs of the
IgG subclass and it is likely that there are NAAs of IgM and
IgA subclasses as well.
NAAs are proposed to have several important functions,
including binding to pathogens, defending against infections,
and removal of senescent or altered molecules, cells, or
tumors.17 The functions of natural anti-MPO, anti-PR3, and
anti-GBM antibodies are still not elucidated. In type 1
diabetes, it has been shown that most individuals possess
anti-GAD65 antibodies, but these are masked in serum by
anti-idiotype antibodies. The lack of anti-idiotype antibodies
rather than the production of autoantibodies is suggested to
be the pathological factor underlying the onset of disease.25
Both PR3 and MPO are released from necrotic or activated
neutrophils and are found circulating in the blood. Thus,
both proteins are presented to the immune system and
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Figure 6 | The cross-reactivity of natural autoantibodies
was measured by antigen inhibition ELISA. (a) The cross-
reactivity of natural anti-MPO antibodies. The binding of
natural anti-MPO antibodies to MPO could be inhibited by
MPO alone, but not by PR3 or NC1. (b) The cross-reactivity of
natural anti-PR3 antibodies. The binding of natural anti-PR3
antibodies to PR3 could be inhibited merely by PR3, but
not by MPO or NC1. (c) The cross-reactivity of natural anti-GBM
antibodies. The binding of natural anti-GBM antibodies to
NC1 could be inhibited by NC1 alone, but not by MPO or PR3.
y axis: the mean absorbance value (OD) of natural autoanti-
bodies bound to the antigen coated in the microtiter plates.
x axis: the concentration of the inhibitor (MPO, PR3, or NC1)
that was preincubated with natural autoantibodies. ELISA,
enzyme-linked immunosorbent assay; GBM, glomerular
basement membrane; MPO, myeloperoxidase;
NC1, noncollagenous; PR3, proteinase 3.
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a scavenging role of the antibodies is plausible, but self-
immunization with complimentary peptides26 is also com-
patible. As NAAs cannot be detected in an IgG manner, we
speculated that they are kept under control by anti-idiotype
antibodies.23 A disturbance of the balance by, for example,
an infection or an uncontrolled inflammation, may result
in ANCA positivity and vasculitis. An alternative explanation
is the existence of ‘hidden autoantibodies’.27 Hidden auto-
antibodies are a subset of IgG that can adapt specific
reactivity on exposure to certain destabilizing conditions,
including low or high pH, chaotropic factors, high salt
concentrations,28 and redox active agents,29 thus including
the elution buffers from either of our affinity columns. These
autoantibodies could be inhibited by the antigen but not by
cross-antigen inhibition assays. Furthermore, it has been
shown that reactivity disappears by adding plasma.28
The coexistence of ANCAs and anti-GBM antibodies is a
common observation, occurring in about one-fourth of all
anti-GBM positive samples and in 10% of ANCA-associated
vasculitis samples. Although the contribution of ‘double-
positive’ antibodies in the pathogenesis of disease is not clear,
it has been shown that there is no cross-reaction between
ANCAs and anti-GBM antibodies.30 In this study, we showed
that all individuals have antigen-specific preformed NAAs
against both ANCA antigens and GBM. In a situation of an
active disease, the idiotypic–anti-idiotypic networks may be
disturbed and one or more of these antibody clones may
become positive, thereby explaining the high incidence of
double-positive samples.
All anti-PR3 and anti-MPO NAA preparations reacted
with peripheral neutrophils when subjected to IIF, and
as predicted, anti-PR3 NAA preparations yielded a c-ANCA
pattern. In most patients with vasculitis, MPO-ANCA
produces a perinuclear (p-ANCA) staining pattern.31
Contrasting to this, all anti-MPO NAA preparations yielded
a c-ANCA pattern. The fact that some anti-MPO anti-
bodies from patients can produce a c-ANCA pattern is well
established. There also exist mouse monoclonal anti-MPO
antibodies that produce a c-ANCA pattern.32 The reason
why anti-MPO can produce different IIF patterns is not
completely clear, but seems to be associated with differences
in epitope specificity. The finding that anti-MPO NAA
preparations produce a c-ANCA pattern, indicates differences
in the fine specificity between NAAs and pathogenic auto-
antibodies, and suggests that an affinity maturation
process has occurred during the development of the
autoantibodies.
Antigen specificity of natural anti-GBM IgG was, in
addition to ELISA and western blot, identified by the linear
deposition along the GBM in normal human renal sections. In
contrast to anti-GBM antibodies from patients, pretreatment
for normal renal sections with 6 mol/l guanidine-HCl was
required for NAA to bind. The most probable explanation is a
difference in affinity. The low affinity of natural anti-GBM
antibodies is not sufficient to induce the required denaturation
of the autoantigen.33 The epitope(s) of natural anti-GBM
antibodies may be restricted to EA and/or EB,
34 which stay in
cryptic conformation and could be recognized only after
denaturation of the native hexameric form.35
We compared characteristics of NAAs against MPO, PR3,
and GBM between Chinese and Swedish individuals and
found a similar tendency, that is, Chinese individuals were
prone to have more NAAs than were Swedish individuals. We
speculate that environmental factors such as the more
opportunities for encountering infectious pathogens by
Chinese individuals might be an explanation. Some peptides
from Staphylococcus aureus show strong homology with
complimentary PR3 (cPR3), and immunization of mice
with cPR3 induced not only antibodies to cPR3 but also
to PR3.26,36 Thus, carriage of S. aureus could induce the
production of antibodies to cPR3 that in turn through
idiotypic anti-idiotypic interactions result in the develop-
ment of natural anti-PR3 antibodies. A similar mechanism of
molecular mimicry may also be involved in the production of
natural anti-MPO and anti-GBM antibodies. Further studies
on the epidemiology of autoimmune diseases could be
helpful to validate this speculation.
In patients with ANCA-associated vasculitis, there is a
huge difference in the anti-PR3/anti-MPO frequencies
between Sweden and China. For example, in Swedish patients
with Wegener’s granulomatosis, 78% are PR3-ANCA posi-
tive37 whereas only 38% in China.38 This phenomenon is not
mirrored when studying NAAs for which all individuals, both
Swedish and Chinese, show equal reactivity to both antigens.
This indicates that other factors are important for the
development of pathogenic autoantibodies associated with
disease. The true ANCA may arise from new unrelated clones
of B cells or affinity maturation of clones already producing
NAAs. To answer this question, studies of V-gene usage and
somatic mutations must be performed.
Table 1 | The percentages of natural autoantibodies against MPO, PR3, and GBM in IgG fractions were compared between
Chinese and Swedish individuals
Chinese individuals Swedish individuals P-value
Natural anti-MPO antibodies (%) 0.19±0.04 0.14±0.04 0.006
Natural anti-PR3 antibodies (%) 0.98±0.30 0.78±0.14 0.064
Natural anti-GBM antibodies (%) 0.68±0.20a 0.37±0.11 0.039
Abbreviations: GBM, glomerular basement membrane; IgG, immunoglobulin G; MPO, myeloperoxidase; PR3, proteinase 3.
aThe percentage of anti-GBM antibodies in sample C10 was much higher than that in the others, and was therefore omitted when calculating the mean percentage of natural
anti-GBM antibodies.
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In conclusion, we have shown that healthy individuals
possess NAAs against MPO, PR3, and GBM in their circu-
lation. Their antigen specificities were confirmed and there
was no cross-reaction between the three kinds of NAAs.
Further investigations are required to elucidate the role
of NAAs in the pathogenesis of the corresponding auto-
immune diseases and in autoimmune regulation of healthy
individuals.
MATERIALS AND METHODS
Plasma
Normal human plasma samples were obtained from 20 healthy
blood donors, 10 from China and 10 from Sweden (Table 2). All the
20 plasma samples were detected to be negative of MPO-ANCA,
PR3-ANCA, or anti-GBM antibodies in routine ELISA. All plasma
samples were stored at 80 1C until used. Informed consents were
obtained from all blood donors.
The sera obtained from 80 consecutive patients with biopsy-
proven ANCA-associated vasculitis were collected from 2007 to 2009
and preserved at 20 1C; 40 of them were MPO-ANCA positive and
the other 40 patients were PR3-ANCA positive. All these patients
were diagnosed at the Renal Division of Peking University First
Hospital. All the sera were obtained on diagnosis before treatment
with plasma exchange or immunosuppression. ANCAs were
screened by IIF assay and antigen-specific ELISA for MPO and
PR3 as described previously.39 Anti-GBM antibodies were detected
by ELISA with negative results.
Preparation of bovine GBM, NC1, and recombinant human
a3(IV)NC1
Bovine GBM was isolated from the glomeruli by differential sieving,
sonication, and collagenase solubilization to form collagenase-
solubilized GBM.40
Bovine testis NC1 was prepared as described previously.41
In brief, bovine testes were decapsulated, ground, and extracted by
3% Triton X-100, resuspended in DNAse (100 KU/ml), extracted
by 6 mol/l guanidine-HCl, and digested by bacterial collagenase.
NC1 domains were purified by a DEAE-Sephacel column.
Recombinant human a3(IV)NC1s were produced as described
previously.41,42 In brief, cDNAs from the NC1 domain of human
type IV collagen a3 were ligated to a type X collagen triple-helix
leader sequence and subcloned into the pcDNA3 vector. Constructs
were then stably transfected into a human embryonic kidney cell line
(HEK 293), and recombinant proteins were harvested and purified
from the medium.
Preparation of affinity columns
In all, 2 ml of silted-up Mini Leak gel (KemEnTech, Copenhagen,
Denmark) was put in a 15 ml tube. After washing (2 1 ml distilled
H2O, centrifugation 15 g for 5 min), 1 mg MPO (a kind gift from
Professor Inge Olsson, Department of Hematology, Lund, Sweden),
1 mg PR3 (Wieslab AB, Lund, Sweden), or 1 mg collagenase-
solubilized GBM in 0.63 ml phosphate-buffered saline (PBS) was
added to 1 ml packed Mini Leak gel together with 0.85 ml coupling
buffer (3.5 mol/l (NH4)2SO4, pH 8.8) and incubated overnight at
room temperature. The gel was then placed in a Pharmacia column
(1 cm in diameter) and rinsed with the coupling buffer for 1 h at a
flow rate of 20 ml/h, followed by 0.1 mol/l etanolamin-HCl to block
active amino acids. Finally, the gel was equilibrated in 50 mmol/l
Tris-HCl pH 7.0, 0.15 mol/l NaCl, 0.02% NaN3.
Isolation of NAAs against MPO, PR3, and GBM
NAAs were isolated as described before.19 In brief, for each of the
20 normal blood donors, IgG fractions were purified from 30 ml
plasma by protein G affinity chromatography (Pharmacia, Uppsala,
Sweden). The normal human IgG preparation of each individual
was divided into three aliquots and then applied to the affinity
columns coupled with MPO, PR3, and GBM. Samples were
circulated in the column for 2 h at room temperature, with
50 mmol/l Tris and 0.15 mol/l NaCl pH 7.5 as the starting buffer
at a flow rate of 0.33 ml/min. NAAs were eluted with 6 mol/l urea
and 50 mmol/l sodium citrate, pH 4.0 as elution buffer, at a flow rate
of 0.5 ml/min. The buffer was immediately exchanged with PBS by
applying the eluate on a PD10 column (Pharmacia).
Detection of the purity of NAAs by gel electrophoresis
NAAs were electrophoresed under reducing conditions in a 10%
NuPAGE gel from Novex (San Diego, CA, USA) in a MOPS buffer
system according to the supplier’s recommendations. Standard
human IgG (ZLB Behring GmbH, Marburg, Germany) was used as
the positive control. Protein bands were silver stained and the
approximate size was identified by the molecular weight size marker
(Fermentas, Helsingborg, Sweden).
Detection of the antigen specificity of NAAs by IIF
In the process of purification, NAAs were concentrated. To render
them comparable with each other and with plasma samples obtained
from patients, we diluted NAAs to the volume of the original plasma
from which they were separated. When assaying, NAAs were then
diluted as required by the specific test.
Natural anti-MPO and anti-PR3 antibodies were screened by the
IIF technique using precooled ethanol-fixed normal peripheral
neutrophils as substrate according to the manufacturer (Euroimmun
AG, Lu¨beck, Germany). NAAs were diluted 1:8. Fluorescence
patterns were classified as either c-ANCA or p-ANCA.
Table 2 | Demographic data of the 20 healthy blood donors
regarding age, gender, and ethnicity
Age (years) Gender Ethnicity
C1 28 Female Mongolian
C2 40 Female Mongolian
C3 29 Female Mongolian
C4 31 Female Mongolian
C5 21 Female Mongolian
C6 35 Male Mongolian
C7 19 Male Mongolian
C8 48 Male Mongolian
C9 26 Male Mongolian
C10 19 Male Mongolian
S1 39 Male N
S2 34 Male N
S3 42 Female N
S4 62 Male N
S5 58 Male N
S6 53 Male N
S7 28 Male N
S8 56 Female N
S9 39 Female N
S10 42 Male N
C, Chinese individuals; N, not known; S, Swedish individuals.
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Natural anti-GBM antibodies were screened for linear deposition
along the glomerular capillary walls by IIF. Frozen tissue sections of
normal human renal specimen were pretreated with 6 mol/l
guanidine-HCl for 1 h at 4 1C, and then incubated with 1% bovine
serum albumin (BSA) for 20 min at 37 1C. NAAs were diluted 1:8
and incubated with the sections for 30 min at 37 1C. Fluorescence
was developed with fluorescein isothiocyanate-conjugated anti-
human IgG antibody (Jackson, Seattle, WA, USA) diluted 1:40 for
30 min at 37 1C. Tissue sections were washed three times between
each step.
Detection of the antigen specificity of NAAs by ELISA
Half of the polystyrene microtiter plates (Nunc immunoplate, Nunc,
Roskilde, Denmark) were coated with 100ml of MPO, PR3, or NC1
at 1.0mg/ml in coating buffer (50 mmol/l sodium carbonate, pH 9.6)
overnight at 4 1C. BSA was used as a nonspecific control antigen
coated in the other half of the plates. In all, 100 ml NAA, diluted 1:40
in PBS with 0.5 mol/l NaCl and 0.2% BSA, was added to each well
and incubated at room temperature for 1 h. Incubation resumed for
1 h with alkaline phosphatase-conjugated goat anti-human IgG (Fc
specific, Sigma, St Louis, MO, USA) diluted 1:4000 in PBS with
0.5 mol/l NaCl, 0.2% BSA, and 0.05% Tween-20. P-nitrophenyl
phosphate (Sigma) at 1 mg/ml in substrate buffer (1 mol/l
diethanolamine, 0.5 mmol/l MgCl2, pH 9.8) was used as the
substrate, and color development was measured spectrophotome-
trically at 405 nm. The plates were washed three times between each
step. All assays were run in duplicate, and when s.e.410% were
found, samples were reanalyzed. Absorbance values from anti-BSA
ELISA were subtracted from results from anti-antigen ELISA. In all,
20 samples of IgG preparations, diluted to the same concentration as
the NAA, were used to set up a cutoff value using meanþ 2 s.d.
Titers of NAA and ANCA from patients with vasculitis
Titers of anti-MPO and anti-PR3 antibodies were detected using
ELISA as described above. The sera were diluted in a two-fold
manner from 1:50 to 1:25,600 and NAAs were diluted from 1:10 to
1:320. Titers were defined as the highest dilution of the sample
which was still positive.
Detection of the antigen specificity of NAAs by western blot
analysis
Recombinant human a3(IV)NC1s were electrophoresed on a 12.5%
SDS polyacrylamide gel at 20 mA under nonreducing conditions.
Proteins were then transferred to a nitrocellulose paper (Schleicher
and Schuell, Maidstone, Kent, UK) by electrophoretic semi-dry
blotting system (Pharmacia) at 0.08 mA/cm2 for 70 min. The
nitrocellulose paper was blocked in TBSTM buffer (0.01 mol/l
Tris-HCl, pH 7.2, 0.15 mol/l NaCl, 0.1% Tween 20, 20 g/l skimmed
milk) for 30 min at room temperature and cut into strips. The strips
were incubated overnight with NAAs diluted 1:10 in TBSTM at 4 1C.
After three washes with TBST, the strips were incubated with
alkaline phosphatase-conjugated secondary antibodies as described
above and diluted 1:6000 in TBSTM for 1 h at room temperature.
The binding was detected by adding the alkaline phosphatase
substrate nitroblue tetrazolium (Sigma) and 5-bromo-4-chloro-3-
indolyl phosphate (Sigma).
Determination of IgG concentrations of NAAs by ELISA
Standard human IgG (ZLB Behring GmbH) was diluted at
decreasing concentrations from 1000 to 1 ng/ml and NAAs were
diluted 1:1000 in coating buffer. Polystyrene microtiter plates
were coated with these samples as described above. Bound IgGs
were detected with alkaline-phosphatase-conjugated secondary
antibodies, as described above. A standard curve was made by
the absorbance value of the standard IgG sample with different
concentration. The IgG concentration of NAAs was calculated by
its absorbance value from the standard curve.
Cross-reactivity among NAAs against MPO, PR3, and GBM
Polystyrene microtiter plates were coated with MPO, PR3, or NC1 as
described above. NAAs were diluted in PBS with 0.5 mol/l NaCl,
0.2% BSA, and 0.05% Tween-20 to obtain approximately the
same absorbance value after 1 h in room temperature. The diluted
NAA preparations were preincubated with MPO, PR3, or NC1 at
increasing concentrations from 0.002 to 2 mg/ml overnight at 4 1C.
The mixtures were transferred onto antigen-coated microtiter plates,
and bound antibodies were detected with alkaline-phosphatase-
conjugated secondary antibodies, as described above. Inhibition
rates were calculated using the following formula:
1 Absorbance value with inhibitor absorbance value with BSA
Absorbance value without inhibitor absorbance value with BSA
Statistical analyses
Data were expressed as mean±s.d. Student’s t-test (mean) was used
in statistical analyses for the comparison between NAAs and sera
obtained from patients with vasculitis and for the comparison of
NAAs between Chinese and Swedish individuals. A P-value o0.05
was considered significant.
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